Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 11 of 15

 
 

Revolution Medicines (NASDAQ:RVMD)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$66.67 (81.4% Upside)

About Revolution Medicines

Revolution Medicines logoRevolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. More about Revolution Medicines
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
4/1/2025Stifel NicolausLower Price TargetBuy ➝ Buy$78.00 ➝ $64.00
3/3/2025HC WainwrightBoost Price TargetBuy ➝ Buy$72.00 ➝ $73.00
2/27/2025WedbushReiterated RatingOutperform$67.00
2/27/2025Stifel NicolausLower Price TargetBuy ➝ Buy$80.00 ➝ $78.00
2/27/2025Needham & Company LLCLower Price TargetBuy ➝ Buy$60.00 ➝ $59.00
1/8/2025UBS GroupBoost Price TargetBuy ➝ Buy$65.00 ➝ $71.00
12/4/2024HC WainwrightBoost Price TargetBuy ➝ Buy$64.00 ➝ $72.00
12/3/2024GuggenheimBoost Price TargetBuy ➝ Buy$82.00 ➝ $87.00
12/3/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $71.00